The influence of St. John's wort on CYP2C19 activity with respect to genotype

Journal of Clinical Pharmacology

Volumn 44, Issue 6, 2004, Pages 577-581

  Wang, Lian Sheng ^a   Zhu, Bing ^a   El Aty, A M Abd ^a   Zhou, Gan ^a   Li, Zhi ^a   Wu, Jun ^b   Chen, Guo Lin ^a   Liu, Jie ^a   Tang, Zhi Rong ^a   An, Wang ^a   Li, Qing ^a   Wang, Dan ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CYP2C19; Drug interactions; Extensive metabolizers; Poor metabolizers; Rifampicin; St. John's wort

Indexed keywords

4' HYDROXYMEPHENYTOIN; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; HYPERICUM PERFORATUM EXTRACT; ISOENZYME; MEPHENYTOIN; PLACEBO;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG URINE LEVEL; ENZYME ACTIVITY; ENZYME INDUCTION; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL; TABLET; VERTIGO;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CAFFEINE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; GENOTYPE; HUMANS; HYPERICUM; MALE; MEPHENYTOIN; MIXED FUNCTION OXYGENASES; PLANT EXTRACTS; POLYMORPHISM, GENETIC;

EID: 2442654207     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004265642     Document Type: Article

References (31)

1. Kasper S: Hypericum perforatum - a review of clinical studies. Pharmacopsychiatry 2001;34(Suppl. 1):S51-S55.
2. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK: St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000;166(3):R11-R16.
3. Yue QY, Bergquist C, Gerden B: Safety of St John's wort (Hypericum perforutum). Lancet 2000;355(9203):576-577.
4. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355: 548-549.
5. Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000;34:1013-1016.
6. Mai I, Krüger H, Budde K, Johne A, Brockmoller J, Neumayer HH, Roots I: Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000;38:500-502.
7. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P: St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54(4):349-356.
8. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Fallon J: Indinavir concentrations and St John's wort. Lancet 2000;355:547-548.
9. Nebel A, Schneider BJ, Baker RK, Kroll DJ: Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33(4):502.
10. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al: St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97(13):7500-7502.
11. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB: Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73(1):41-50.
12. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD: The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-326.
13. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, et al: Effect of the gene dosage of CgammaP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 1999;66(6):642-646.
14. Kupfer A, Roberts RK, Schenker S, Branch RA: Stereoselective metabolism of mephenytoin in man. J Pharmacol Exp Ther 1981; 218(1):193-199.
15. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al: Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33(7): 1743-1752.
16. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, et al: Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clin Pharmacol Ther 2001;70(5):455-461.
17. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al: Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7(1):59-64.
18. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, et al: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997;281(1):604-609.
19. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, et al: Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002;54(5):540-543.
20. Xie HG, Huang SL, Zhou HH: High-performance liquid chromatographic determination of urinary 4′-hydroxymephenytoin, a metabolic marker for the hepatic enzyme CYP2C19, in humans. J Chromatogr B Biomed Appl 1995;668(1):125-131.
21. Chen Y, Ferguson SS, Negishi M, Goldstein JA: Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 2003;64(2):316-324.
22. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR: Induction of polymorphic 4′-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol 1990;30(3):471-475.
23. Feng HJ, Huang SL, Wang W, Zhou HH: The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol 1998; 45(1):27-29.
24. Johne A, Schmider J, Brockmoller J, Stadelmann AM, Stormer E, Bauer S, et al: Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002;22(1):46-54.
25. Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294(1):88-95.
26. Karyekar CS, Eddington ND, Dowling TC: Effect of St. John's Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med 2002;48:97-100.
27. Morimoto T, Kotegawa T, Tsutsumi K, Ohtani Y, Imai H, Nakano S: Effect of St. John's wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004;44:95-101.
28. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, et al: Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002;72(3): 276-287.
29. Goodwin B, Hodgson E, Liddle C: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 1999;56(6):1329-1339.
30. Finch CK, Chrisman CR, Baciewicz AM, Self TH: Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162(9): 985-992.
31. Wietholtz H, Zysset T, Marschall HU, Generet K, Matern S: The influence of rifampin treatment on caffeine clearance in healthy man. J Hepatol 1995;22(1):78-81.